SWOBY (Swedish Orphan Biovitrum AB) Moat Score: 6/10 (As of Jun. 25, 2026)


SWOBY Swedish Orphan Biovitrum AB SWOBY
67 GF Score
Price $23.18
GF Value $17.20
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Swedish Orphan Biovitrum AB Moat Score?

Swedish Orphan Biovitrum AB SWOBY 67 Moat Score is 6 as of Jun. 25, 2026. GuruFocus rates SWOBY with a GF Score™ of 67/100 and a GF Value™ of $17.20 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 1,033 Drug Manufacturers companies, Swedish Orphan Biovitrum AB ranks better than 97.1% on this metric.

Swedish Orphan Biovitrum AB has the Moat Score of 6, which implies that the company might have Narrow Moat - Strong narrow moat, clearly distinguishable but not wide.

Swedish Orphan Biovitrum AB has Narrow Moat: Swedish Orphan Biovitrum AB has a strong narrow moat with valuable intellectual property and a solid market position in niche pharmaceuticals. It benefits from regulatory barriers and customer loyalty, but lacks the scale for a wide moat.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Swedish Orphan Biovitrum AB might have Narrow Moat - Strong narrow moat, clearly distinguishable but not wide.

Swedish Orphan Biovitrum AB  (OTCPK:SWOBY) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Swedish Orphan Biovitrum AB Moat Score Related Terms

SWOBY vs ZTS: Moat Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Swedish Orphan Biovitrum AB's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Swedish Orphan Biovitrum AB Moat Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Swedish Orphan Biovitrum AB's Moat Score distribution charts can be found below:

* The bar in red indicates where Swedish Orphan Biovitrum AB's Moat Score falls into.


SWOBY
67GF Score
Swedish Orphan Biovitrum AB SWOBY
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 6 mean?
Swedish Orphan Biovitrum AB (SWOBY) has a Moat Score of 6 as of Jun. 25, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Swedish Orphan Biovitrum AB ranks #30 out of 1033 companies in the Drug Manufacturers industry, placing it in the top 2.9%.
Is Swedish Orphan Biovitrum AB's Moat Score too high?
Swedish Orphan Biovitrum AB's current Moat Score is 6. Based on the distribution chart, Swedish Orphan Biovitrum AB ranks #30 out of 1033 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Swedish Orphan Biovitrum AB has a GF Score™ of 67/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Swedish Orphan Biovitrum AB's Moat Score compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Swedish Orphan Biovitrum AB ranks #30 out of 1033 companies for Moat Score. This places Swedish Orphan Biovitrum AB in the top 3% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Drug Manufacturers company?
A good Moat Score depends on the Drug Manufacturers industry context. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. Swedish Orphan Biovitrum AB's current Moat Score is 6. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Swedish Orphan Biovitrum AB stock overvalued right now?
Based on GuruFocus' analysis, Swedish Orphan Biovitrum AB (SWOBY) is currently considered Significantly Overvalued. The stock's GF Value™ is $17.20, compared to a current price of $23.18 — trading 34.8% above its estimated fair value. The current Moat Score is 6. Swedish Orphan Biovitrum AB's overall GF Score™ is 67/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Swedish Orphan Biovitrum AB (SWOBY), the current Moat Score is 6 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Swedish Orphan Biovitrum AB (SWOBY) Overvalued in 2026?

Based on GuruFocus' analysis, Swedish Orphan Biovitrum AB stock appears to be overvalued. The current stock price of $23.18 is trading 34.8% above its estimated GF Value™ of $17.20. GuruFocus considers Swedish Orphan Biovitrum AB to be Significantly Overvalued.

Key valuation signals for SWOBY:

  • Moat Score: 6
  • GF Value™: $17.20 vs. price of $23.18 (34.8% above fair value)
  • GF Score™: 67/100 with 7 warning signs

No single metric tells the full story. See the SWOBY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Swedish Orphan Biovitrum AB Business Description

Address Norra Stationsgatan 93A, Stockholm, SWE, SE-112 76
Swedish Orphan Biovitrum, or Sobi, focuses on rare diseases, primarily in hematology and immunology. Biovitrum started with experience in studying recombinant proteins such as hemophilia factors, and partnered with Syntonix (now part of Sanofi) in 2006 on long-acting hemophilia factor replacement programs. Biovitrum acquired Orfadin and a partnered product business with the acquisition of Swedish Orphan. Sobi launched hemophilia products Alprolix and Eloctate in Europe in 2016, and Altuvoct in 2024. Sobi has been building its immunology pipeline (rare-disease drug Gamifant, US rights to RSV antibodies Synagis and Beyfortus, gout drugs, complement drug Aspaveli) and a broader hematology pipeline (thrombocytopenia drug Doptelet, blood cancer drug Zynlonta, myelofibrosis drug Vonjo).
67GF Score

Get the complete analysis for SWOBY

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$23.18
Price
$17.20
GF Value